Wednesday, April 25, 2018
BRIEF-European Commission Approves Bristol-Myers Squibb's Opdivo 4-Week Dosing Schedule
* EUROPEAN COMMISSION APPROVES BRISTOL-MYERS SQUIBB’S OPDIVO (NIVOLUMAB) FOUR-WEEK DOSING SCHEDULE FOR ADVANCED MELANOMA AND PREVIOUSLY TREATED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment